Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Slides:

Advertisements

Similar presentations

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Advertisements

Overall (regardless of smoking Hx) Prior or current smoking Hx

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Advances in Molecular Biology of Lung Disease

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma Maria I. Toki, MD,

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB (Alliance) Arnaud Augert, PhD,

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse Karinna.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens Judith N. Müller, PhD, Markus Falk, PhD, Jatin Talwar, MSc, Nicole.

Volume 150, Issue 3, Pages (September 2018)

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin.

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification Anna Karlsson, MSc,

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer Alexa B. Schrock, PhD, Allison.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants Ugo Pastorino, MD, Roberto Boffi, MD, Alfonso Marchianò, MD,

Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the.

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Clinicopathologic Features of Advanced Squamous NSCLC

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Matthias Scheffler, MD, Michaela A

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Journal of Thoracic Oncology

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune.

Presentation transcript:

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher, ScD, Matteo Dugo, PhD, Andrea Devecchi, MSc, Katherine Drake, PhD, Stefano Sestini, MD, Paola Suatoni, MSc, Elisa Romeo, PhD, Gabriella Sozzi, PhD, Ugo Pastorino, MD, Mattia Boeri, PhD Journal of Thoracic Oncology Volume 12, Issue 6, Pages 922-931 (June 2017) DOI: 10.1016/j.jtho.2017.03.001 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Mutation plot of 94 low-dose computed tomography screening–detected lung tumors. Co-mutation plot of genes mutated in at least one of the 94 National Cancer Institute samples (upper panel) and clinicopathologic and molecular characteristics of patients (lower panel). Genes are ranked according to the number of mutated samples. Tumor protein p53 gene (TP53) was altered in 44 cases and KRAS in 27, followed by alteration of serine/threonine kinase 11 gene (STK11) and cyclin-dependent kinase inhibitor 2A gene (CDKN2A) (seven tumors each), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) (six), phosphatase and tensin homolog gene (PTEN) (four), EGFR (one L858R and three exon 19 ELREA deletions), and catenin beta 1 gene (CTNNB1) (four, twice together); APC, WNT signaling pathway regulator gene (APC), BRAF, and NRAS (two each); and 12 other genes that were mutated in one sample each. MET, MNNG HOS Transforming gene; SMAD4, SMAD family member 4 gene; ATM serine/threonine kinase (ATM), gene; FGFR1, fibroblast growth factor receptor 1 gene; FGFR2, fibroblast growth factor receptor 2 gene; MLH1, mutL homolog 1 gene; RET, ret proto-oncogene; ERBB4, erb-b2 receptor tyrosine kinase 4 gene; FBXW7, F-box and WD repeat domain containing 7 gene; RB1, retinoblastoma 1 gene; SMO, smoothened, frizzled class receptor gene; SMARCB1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 gene; MSC, microRNA signature classifier; ADC, adenocarcinoma; SCC, squamous cell carcinoma; neuroendocrine tumor; NA, not available. Journal of Thoracic Oncology 2017 12, 922-931DOI: (10.1016/j.jtho.2017.03.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Clinicopathologic characteristics associated with mutational status of tumor protein p53 gene (TP53) and KRAS. (A) Box plot reporting the distribution of pack-years index according to TP53 mutational status: p value for two-tailed Mann-Whitney test. (B) Kaplan-Meier curve in strata of KRAS mutational status. Overall survival (OS) and p value for log-rank test are reported. mut, mutation; wt, wild type. Journal of Thoracic Oncology 2017 12, 922-931DOI: (10.1016/j.jtho.2017.03.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Kaplan-Meier analysis according to mutational status and microRNA signature classifier (MSC). Kaplan-Meier curves in strata of mutational status alone (A), the combination of mutational status and MSC (B), and the combination of mutational status, MSC, and tumor stage (C). MSC risk level: high (H), intermediate (I), and low (L). Overall survival (OS) and p value for log-rank test are reported. Journal of Thoracic Oncology 2017 12, 922-931DOI: (10.1016/j.jtho.2017.03.001) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions